title: Double blind, randomised, placebo controlled study of oral vancomycin in prevention of necrotising enterocolitis in preterm, very low birthweight infants.
abstract: OBJECTIVE
  To evaluate the effectiveness of oral vancomycin in the prophylaxis of necrotising enterocolitis in preterm, very low birthweight infants.
  
  
  METHODS
  A prospective, double blind, randomised, placebo controlled study in a tertiary referral centre of a university teaching hospital was conducted on 140 very low birthweight infants consecutively admitted to the neonatal unit. The babies were randomly allocated to receive oral vancomycin (15 mg/kg every 8 hours for 7 days) or an equivalent volume of placebo solution. Prophylaxis was started 24 hours before the start of oral feeds. All suspected cases of necrotising enterocolitis were investigated with a full sepsis screen and serial abdominal radiographs. Necrotising enterocolitis was diagnosed and staged according to modified Bell's criteria.
  
  
  RESULTS
  Nine of 71 infants receiving oral vancomycin and 19 of 69 infants receiving the placebo solution developed necrotising enterocolitis (p = 0.035). Infants with necrotising enterocolitis were associated with a significant increase in mortality (p = 0.026) and longer duration of hospital stay (p = 0.002).
  
  
  CONCLUSIONS
  Prophylactic oral vancomycin conferred protection against necrotising enterocolitis in preterm, very low birthweight infants and was associated with a 50% reduction in the incidence. However, widespread implementation of this preventive measure is not recommended, as it would only be effective in necrotising enterocolitis caused by Gram positive organisms and could increase the danger of the emergence of vancomycin resistant or dependent organisms. Its use should be restricted to a high prevalence nursery for a short and well defined period in a selected group of high risk patients.
authors.affiliation: Department of Paediatrics, Prince of Wales Hospital, Chinese University of Hong Kong, People's Republic of China.
authors.forename: Y K
authors.initials: YK
authors.lastname: Siu
authors.forename: P C
authors.initials: PC
authors.lastname: Ng
authors.forename: S C
authors.initials: SC
authors.lastname: Fung
authors.forename: C H
authors.initials: CH
authors.lastname: Lee
authors.forename: M Y
authors.initials: MY
authors.lastname: Wong
authors.forename: T F
authors.initials: TF
authors.lastname: Fok
authors.forename: K W
authors.initials: KW
authors.lastname: So
authors.forename: K L
authors.initials: KL
authors.lastname: Cheung
authors.forename: W
authors.initials: W
authors.lastname: Wong
authors.forename: A F
authors.initials: AF
authors.lastname: Cheng
mesh_terms: D000284:Administration, Oral; D000900:Anti-Bacterial Agents / Q000008:administration & dosage*; D004311:Double-Blind Method; D020345:Enterocolitis, Necrotizing / Q000401:mortality / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D007902:Length of Stay; D008297:Male; D011446:Prospective Studies; D014640:Vancomycin / Q000008:administration & dosage*
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin